1. Home
  2. CET vs ANIP Comparison

CET vs ANIP Comparison

Compare CET & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

HOLD

Current Price

$52.81

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$79.50

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CET
ANIP
Founded
1929
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
CET
ANIP
Price
$52.81
$79.50
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$110.00
AVG Volume (30 Days)
35.2K
290.8K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
5.11%
N/A
EPS Growth
N/A
419.23
EPS
N/A
3.32
Revenue
N/A
$206,547,000.00
Revenue This Year
N/A
$21.01
Revenue Next Year
N/A
$17.59
P/E Ratio
$6.93
$24.02
Revenue Growth
N/A
2.47
52 Week Low
$43.19
$56.71
52 Week High
$53.88
$99.50

Technical Indicators

Market Signals
Indicator
CET
ANIP
Relative Strength Index (RSI) 65.39 53.27
Support Level $49.88 $77.54
Resistance Level N/A $83.87
Average True Range (ATR) 0.79 2.86
MACD 0.22 0.21
Stochastic Oscillator 78.17 60.60

Price Performance

Historical Comparison
CET
ANIP

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: